Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.64 |
| ▸ | CTSK | P43235 | 2/20 | 0.64 |
| ▸ | CTSL | P07711 | 1/20 | 0.64 |
| ▸ | CTSB | P07858 | 1/20 | 0.64 |
| ▸ | ACE | P12821 | 1/20 | 0.61 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.60 |
| ▸ | PPARA | Q07869 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | TACR1 | P25103 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.56 |
| ▸ | AKT1 | P31749 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22404737 | 1.00 | CTSS (0.64) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL3355326 | 1.00 | CTSS (0.64) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL16163459 | 0.95 | CTSS (0.63) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL7409389 | 0.95 | CTSS (0.65) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL27487987 | 0.95 | CTSS (0.65) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL7409385 | 0.95 | CTSS (0.65) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL7235877 | 0.95 | CTSS (0.63) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL1486267 | 0.95 | CTSS (0.63) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL27487988 | 0.95 | CTSS (0.65) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL3821800 | 0.95 | CTSS (0.65) | CTSSCTSKCTSLCTSBACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113366011-B | Process for producing peptide compound | 日产化学株式会社 | 2024-08-16 | — | — | CN | disclosed |
| US-11993629-B2 | Method for producing peptide compound | NISSAN CHEMICAL CORPORATION (JP) | 2024-05-28 | — | — | US | disclosed |
| US-20220106355-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2022-04-07 | — | — | US | disclosed |
| EP-3922638-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | Nissan Chemical Corporation (JP) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020162393-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | 日産化学株式会社 | 2020-08-13 | — | — | WO | disclosed |
| CN-110167921-A | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | 勃林格殷格翰动物保健美国公司 | 2019-08-23 | — | — | CN | disclosed |
| US-20160347792-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-12-01 | — | — | US | disclosed |
| US-9441012-B2 | Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors | TRILLIUM THERAPEUTICS INC. (CA) | 2016-09-13 | — | — | US | disclosed |
| US-9257576-B2 | Amino acid generator and polysiloxane composition containing the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-02-09 | — | — | US | disclosed |
| US-20150274777-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | HOFFMANN-LA ROCHE INC. | 2015-10-01 | — | — | US | disclosed |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| EP-1306367-B1 | SULFONIC ACID DERIVATIVES OF HYDROXAMIC ACIDS AND THEIR USE AS MEDICINAL PRODUCTS | MITSUBISHI PHARMA CORP (JP) | 2007-07-18 | — | — | EP | disclosed |
| US-7232818-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-6989401-B2 | Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products | MITSUBISHI PHARMA CORPORATION (JP) | 2006-01-24 | — | — | US | disclosed |
| CN-1169809-C | Beta-tetrahydro carboline carboxylic acid, its RGD conjugate, their synthesis and medical application | 浙江医药股份有限公司新昌制药厂 | 2004-10-06 | — | — | CN | disclosed |
| US-20030176486-A1 | Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products | MITSUBISHI PHARMA CORPORATION (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1306367-A1 | SULFONIC ACID DERIVATIVES OF HYDROXAMIC ACIDS AND THEIR USE AS MEDICINAL PRODUCTS | Welfide Corporation (JP) | 2003-05-02 | — | — | EP | disclosed |
| CN-1370778-A | Beta-tetrahydro carboline carboxylic acid, its RGD conjugate, their synthesis and medical application | XINCHANG PHARMACEUTICAL FACTORY ZHEJIANG MEDICINE CO LTD (CN) | 2002-09-25 | — | — | CN | disclosed |
| US-4223132-A | Selective conversion of benzyl alcohol carboxylates to the free acid form | SHIONOGI & CO., LTD. (JP) | 1980-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347792-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | PSMB5, PSMB1, PSMB7 | CTSS 1116/4885CTSK 78/4885CTSL 2486/4885 |
| US-20030176486-A1 | Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products | HDAC5, STS, LITAF | CTSS 2001/4885CTSK 2590/4885CTSL 1665/4885 |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, CPN1 | CTSS 107/4885CTSK 122/4885CTSL 174/4885 |
| US-11993629-B2 | Method for producing peptide compound | VIP, NGLY1, IAPP | CTSS 438/4885CTSK 978/4885CTSL 198/4885 |
| US-20150274777-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | PSMB7, PSMB5, PSMC2 | CTSS 131/4885CTSK 114/4885CTSL 554/4885 |
| US-20220106355-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | VIP, NGLY1, IAPP | CTSS 438/4885CTSK 978/4885CTSL 198/4885 |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, PSMB1 | CTSS 100/4885CTSK 128/4885CTSL 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.